ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

iloperidone

Also written as “Iloperidone”, “Iloperidone 1 MG” and “iloperidone (oral tablet)”.

Its studies are mostly in Schizophrenia · Hypertension · Parkinson Disease, led by 4 companies.

Drug pageIloperidone: every studyAll 20 studies of it, academic ones too, with its approvals, label and forms.
Furthest: phase 4, since Dec 5, 202215 company-led studies, 3 open or runningNext primary completion: Nov 2027 (phase 3)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Vanda Pharmaceuticalsits history only103 open or runningphase 4since Dec 5, 2022Nov 10, 2005Nov 2027phase 3 · NCT06961968
CSPC Pharmaceutical Group20 open or runningphase 3since May 19, 2015May 19, 2015none ahead
Novartisits history only20 open or runningphase 4since Sep 19, 2010Sep 19, 2010none ahead
Hansoh Pharmaceutical Groupits history only10 open or runningphase 2since Jun 17, 2012Jun 17, 2012none ahead

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and studies of CSPC Pharmaceutical Group only; the figures above count every company.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. May 19, 2015First study: phase 3 study in SchizophreniaFirst studyNCT02453893 · 288 enrolled · China
  2. Jan 19, 2018Phase 1 study in BioequivalenceNCT03420534 · 36 enrolled · China

TargetBeta

DRD2 →HTR2A →read by rule
“Dopamine D2 receptor antagonist; Serotonin 2a (5-HT2a) receptor antagonist”ChEMBL 37, by rule

Other programs on the same two targets

ProgramCompanyFurthest phaseStudies
AripiprazoleruleOtsukaphase 4131
RisperidoneruleJohnson & Johnsonphase 4111
paliperidoneruleJohnson & Johnsonphase 4106
OlanzapineruleEli Lillyphase 476
brexpiprazoleruleOtsukaphase 470
lurasidoneruleSumitomo Pharmaphase 452
lumateperoneruleJohnson & Johnsonphase 325

Studies

All 2 CSPC Pharmaceutical Group leads, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT03420534Bioequivalence · China1UNKNOWNDec 14, 201736
NCT02453893Schizophrenia · China3UNKNOWNJun 2015288

How it is read

Names in the registry

  • “Iloperidone”, 9 entries
  • “iloperidone”, 4 entries
  • “Iloperidone 1 MG”, 1 entry
  • “iloperidone (oral tablet)”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.